PMC8010235_01
Pretreatment biopsy. (A) Histological aspect of lung adenocarcinoma (HE staining), (B) Intense cytoplasmic ALK protein expression on immunohistochemistry. HE, hematoxylin-eosin; ALK, anaplastic lymphoma kinase.
fonc-11-655856-g001.jpg
PMC8010235_01_fonc-11-655856-g001.jpg
f1
Simultaneously, the positive ALK expression was detected by Ventana immunohistochemistry (IHC) staining ( Figure 1 ).
Radiological evaluation of the primary tumor and lymph nodes. (A) Baseline, (B) After 3 chemotherapy cycles, (C) After 2 months of crizotinib treatment.
fonc-11-655856-g002.jpg
PMC8010235_01_fonc-11-655856-g002.jpg
f2
Contrast chest computed tomography (CT) after 3 cycles of gemcitabine plus cisplatin showed that the primary tumor remained stable according to the RECIST 1.1 criteria compared with the initial CT scan ( Figures 2A, B ). Encouragingly, the patient was downstaged to cT2aN2M0 within 2 months ( Figure 2C ).
Radiological evaluation of intracranial oligometastasis. (A) Initial detection, (B) Five months after stereotactic radiosurgery.
fonc-11-655856-g003.jpg
PMC8010235_01_fonc-11-655856-g003.jpg
f3
Five months after SRS, the intracranial oligometastasis showed a complete response based on the RECIST 1.1 criteria ( Figure 3 ).